Literature DB >> 15650194

CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia.

H Blaak1, P H M Boers, R A Gruters, H Schuitemaker, M E van der Ende, A D M E Osterhaus.   

Abstract

Human immunodeficiency virus type 2 (HIV-2) is generally considered capable of using a broad range of coreceptors. Since HIV-2 variants from individuals with nonprogressive infection were not studied previously, the possibility that broad coreceptor usage is a property of variants associated with progressive infection could not be excluded. To test this, we determined the coreceptor usage of 43 HIV-2 variants isolated from six long-term-infected individuals with undetectable plasma viremia. Using GHOST indicator cells, we showed for the first time that the only coreceptors efficiently used by low-pathogenic HIV-2 variants are CCR5, GPR15 (BOB), and CXCR6 (BONZO). Surprisingly, control HIV-2 variants (n = 45) isolated from seven viremic individuals also mainly used these three coreceptors, whereas use of CCR1, CCR2b, or CCR3 was rare. Nearly a quarter of all HIV-2 variants tested could infect the parental GHOST cells, which could be partially explained by CXCR4 usage. Use of CXCR4 was observed only for HIV-2 variants from viremic individuals. Thirty-eight variants from aviremic and viremic HIV-2-infected individuals were additionally tested in U87 cells. All except one were capable of infecting the parental U87 cells, often with high efficiency. When virus production in parental cells was regarded as background in the coreceptor-transduced cell lines, the results in U87 cells were largely in agreement with the findings in GHOST cells. HIV-2 isolates from aviremic individuals commonly use as coreceptors CCR5, GPR15, and CXCR6, as well as an unidentified receptor expressed by U87 cells. Broad coreceptor usage, therefore, does not appear to be associated with pathogenicity of HIV-2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15650194      PMCID: PMC544080          DOI: 10.1128/JVI.79.3.1686-1700.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Identification of a major co-receptor for primary isolates of HIV-1.

Authors:  H Deng; R Liu; W Ellmeier; S Choe; D Unutmaz; M Burkhart; P Di Marzio; S Marmon; R E Sutton; C M Hill; C B Davis; S C Peiper; T J Schall; D R Littman; N R Landau
Journal:  Nature       Date:  1996-06-20       Impact factor: 49.962

2.  The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.

Authors:  H Choe; M Farzan; Y Sun; N Sullivan; B Rollins; P D Ponath; L Wu; C R Mackay; G LaRosa; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

3.  Coreceptor requirements of primary HIV type 1 group O isolates from Cameroon.

Authors:  M T Dittmar; L Zekeng; L Kaptue; J Eberle; H G Kräusslich; L Gürtler
Journal:  AIDS Res Hum Retroviruses       Date:  1999-05-20       Impact factor: 2.205

4.  Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

Authors:  T Murakami; T Y Zhang; Y Koyanagi; Y Tanaka; J Kim; Y Suzuki; S Minoguchi; H Tamamura; M Waki; A Matsumoto; N Fujii; H Shida; J A Hoxie; S C Peiper; N Yamamoto
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

5.  An orphan G protein-coupled receptor, GPR1, acts as a coreceptor to allow replication of human immunodeficiency virus types 1 and 2 in brain-derived cells.

Authors:  N Shimizu; Y Soda; K Kanbe; H Y Liu; A Jinno; T Kitamura; H Hoshino
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors.

Authors:  B J Doranz; J Rucker; Y Yi; R J Smyth; M Samson; S C Peiper; M Parmentier; R G Collman; R W Doms
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

7.  Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.

Authors:  S J Popper; A D Sarr; K U Travers; A Guèye-Ndiaye; S Mboup; M E Essex; P J Kanki
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

8.  Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.

Authors:  A M de Roda Husman; R P van Rij; H Blaak; S Broersen; H Schuitemaker
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

9.  HIV-2 infection in 12 European residents: virus characteristics and disease progression.

Authors:  M E van der Ende; M Schutten; T D Ly; R A Gruters; A D Osterhaus
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

10.  HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages.

Authors:  A McKnight; P R Clapham; R A Weiss
Journal:  Virology       Date:  1994-05-15       Impact factor: 3.616

View more
  35 in total

1.  Phosphorylation-dependent C-terminal binding of 14-3-3 proteins promotes cell surface expression of HIV co-receptor GPR15.

Authors:  Yukari Okamoto; Sojin Shikano
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

2.  In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors.

Authors:  Benoit Visseaux; Charlotte Charpentier; Margarita Hurtado-Nedelec; Alexandre Storto; Romain Antoine; Gilles Peytavin; Florence Damond; Sophie Matheron; Françoise Brun-Vézinet; Diane Descamps
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

Review 3.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 4.  Natural killer cell memory.

Authors:  Silke Paust; Ulrich H von Andrian
Journal:  Nat Immunol       Date:  2011-06       Impact factor: 25.606

5.  Differential expression of GPR15 on T cells during ulcerative colitis.

Authors:  Alexandra Adamczyk; Daniel Gageik; Annika Frede; Eva Pastille; Wiebke Hansen; Andreas Rueffer; Jan Buer; Jürgen Büning; Jost Langhorst; Astrid M Westendorf
Journal:  JCI Insight       Date:  2017-04-20

6.  CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals.

Authors:  Anabela C P Picton; Maria Paximadis; Richard E Chaisson; Neil A Martinson; Caroline T Tiemessen
Journal:  Clin Immunol       Date:  2017-04-18       Impact factor: 3.969

7.  Efficient Nef-mediated downmodulation of TCR-CD3 and CD28 is associated with high CD4+ T cell counts in viremic HIV-2 infection.

Authors:  Mohammad Khalid; Hangxing Yu; Daniel Sauter; Shariq M Usmani; Jan Schmokel; Jerome Feldman; Rob A Gruters; Marchina E van der Ende; Matthias Geyer; Sarah Rowland-Jones; Albert D Osterhaus; Frank Kirchhoff
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

8.  The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease.

Authors:  Ma'en Obeidat; Xiaoting Ding; Nick Fishbane; Zsuzsanna Hollander; Raymond T Ng; Bruce McManus; Scott J Tebbutt; Bruce E Miller; Stephen Rennard; Peter D Paré; Don D Sin
Journal:  Nicotine Tob Res       Date:  2016-05-06       Impact factor: 4.244

9.  Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infection.

Authors:  Rui Soares; Russell Foxall; Adriana Albuquerque; Catarina Cortesão; Miguel Garcia; Rui M M Victorino; Ana E Sousa
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

10.  Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection.

Authors:  Melody G Duvall; Karin Loré; Hetty Blaak; David A Ambrozak; William C Adams; Kathlyn Santos; Christof Geldmacher; John R Mascola; Andrew J McMichael; Assan Jaye; Hilton C Whittle; Sarah L Rowland-Jones; Richard A Koup
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.